-- ハーキュリーズ・メタルズ（BIG.V）は水曜日、私募増資による資金調達額を当初予定の2,320万ドルから3,150万ドルに増額したと発表した。 同社は、引受会社に対し、1株あたり0.59ドルで3,640万株を売却し、2,140万ドルを調達した。 また、ブローカーを介した私募増資により、1株あたり0.59ドルで1,700万株を1,000万ドルで調達する予定である。 バリック・マイニング（ABX.TO）は、ハーキュリーズへの出資比率を維持する参加権を有しているが、ハーキュリーズは、バリックが今回の増資に参加する予定があるかどうかについては明らかにしていない。 調達資金は、アイダホ州西部にある同社が100%所有するハーキュリーズ鉱区の探査・開発、および運転資金に充当される。 同社の株価は、トロント証券取引所ベンチャー市場で0.01ドル安の0.63ドルで取引されている。
Price: $0.63, Change: $-0.01, Percent Change: -1.56%
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%